Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Sells $610,573.70 in Stock

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) COO Pad Chivukula sold 17,435 shares of the firm’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $35.02, for a total value of $610,573.70. Following the completion of the sale, the chief operating officer now directly owns 473,448 shares of the company’s stock, valued at approximately $16,580,148.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Pad Chivukula also recently made the following trade(s):

• On Tuesday, March 19th, Pad Chivukula sold 8,565 shares of Arcturus Therapeutics stock. The stock was sold at an average price of $35.01, for a total value of $299,860.65.

Arcturus Therapeutics Trading Up 2.8 %

Shares of NASDAQ:ARCT opened at $33.77 on Friday. Arcturus Therapeutics Holdings Inc. has a 12-month low of $17.52 and a 12-month high of $43.81. The company has a market capitalization of $908.92 million, a PE ratio of -32.47 and a beta of 2.64. The business has a 50 day moving average of $36.21 and a two-hundred day moving average of $29.40.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Blair William & Co. IL acquired a new position in Arcturus Therapeutics in the third quarter valued at approximately $478,000. AQR Capital Management LLC lifted its holdings in Arcturus Therapeutics by 239.8% in the third quarter. AQR Capital Management LLC now owns 172,202 shares of the biotechnology company’s stock valued at $4,400,000 after acquiring an additional 121,526 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in Arcturus Therapeutics in the third quarter valued at approximately $2,738,000. Stratos Wealth Partners LTD. acquired a new position in Arcturus Therapeutics in the third quarter valued at approximately $301,000. Finally, Jupiter Asset Management Ltd. acquired a new position in Arcturus Therapeutics in the third quarter valued at approximately $4,977,000. 94.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have weighed in on ARCT. Canaccord Genuity Group initiated coverage on Arcturus Therapeutics in a report on Wednesday, December 13th. They issued a “buy” rating and a $90.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a report on Friday, March 8th. Citigroup lifted their target price on Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 8th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a report on Wednesday, March 20th. Finally, Canaccord Genuity Group initiated coverage on Arcturus Therapeutics in a report on Wednesday, December 13th. They set a “buy” rating for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Arcturus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $61.33.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.